MeSH D017497 - hidradenitis suppurativa
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Biocon | Adalimumab | Hulio |  | 2020-07-06 |  |  |
| Sandoz | Adalimumab | Halimatoz |  | 2018-07-26 |  |  |
| Adalimumab | Hefiya |  | 2018-07-26 |  |  | |
| Adalimumab | Hyrimoz |  | 2018-10-30 |  |  | |
| Boehringer Ingelheim | Adalimumab | Cyltezo |  | 2017-08-25 |  |  |
| AbbVie | Adalimumab | Humira |  | 2002-12-31 | $10,615 M | Q4/23-Q3/24 |
| Pfizer | Adalimumab | Abrilada |  | 2019-11-15 |  |  |
| Adalimumab | Amsparity |  | 2020-02-13 |  |  | |
| Abbott Biotherapeutics | Adalimumab | Trudexa |  | 2003-09-01 |  |  |
| Celltrion | Adalimumab | Yuflyma |  | 2023-05-23 |  |  |
| Fresenius Kabi | Adalimumab | Idacio |  | 2022-12-13 |  |  |
| Adalimumab | Kromeya |  | 2019-04-02 |  |  | |
| Amgen | Adalimumab | Amgevita |  | 2017-03-21 |  |  |
| Adalimumab | Amjevita |  | 2016-09-23 |  |  | |
| Adalimumab | Solymbic |  | 2017-03-22 |  |  | |
| Stada Arzneimittel | Adalimumab | Hukyndra |  | 2021-11-15 |  |  |
| Adalimumab | Libmyris |  | 2021-11-12 |  |  |
1
2
>
Clinical Trials
Historical Success Rate
Phase 1
50%5/10
Phase 2
7%2/29
Phase 3
50%3/6
Approved: 2Overall Success rate: 2%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use